Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 16 of 58, showing 10 Applications out of 576 total, starting on record 151, ending on 160

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

151.

ECCT/17/08/07   Tambua Mapema Plus
    Impact of a novel HIV-1 RNA testing intervention to detect acute and prevalent HIV infection and reduce HIV transmission – Tambua Mapema Plus   
Principal Investigator(s)
1. Eduard J Sanders
2. Susan M Graham
Site(s) in Kenya
KEMRI Mtwapa Research Clinic
 
25-08-2017 View

152.

ECCT/17/05/02   The Anza Mapema Study
    Expanding test and treat for HIV prevention in MSM in Kisumu, Kenya: The Anza Mapema Study   
Principal Investigator(s)
1. Fredrick Odhiambo Otieno
Site(s) in Kenya
Anza Mapema Study Clinic
 
01-09-2017 View

153.

ECCT/17/08/01   A trial to compare the safety and immune response of the normal full and reduced doses of yellow fever vaccines in Kenyan adults
    A Phase IV randomized, double blinded non-inferiority trial on the immunogenicity and safety of fractional doses of yellow fever vaccines.   
Principal Investigator(s)
1. Philip Bejon
Site(s) in Kenya
KEMRI Kilifi
 
07-09-2017 View

154.

ECCT/17/08/02   IMPROVE (Improving PRegnancy Outcomes with intermittent PReVEntive treatment in Africa)
    IPTp with dihydroartemisinin-piperaquine and azithromycin for malaria, sexually transmitted and reproductive tract infections in pregnancy in high sulphadoxine-pyrimethamine resistance areas in Kenya, Malawi and Tanzania: an international multi-centre 3-arm placebo-controlled trial   
Principal Investigator(s)
1. Simon Kariuki
Site(s) in Kenya
1. Migori County Referral Hospital (Migori county)
2. Homa Bay County Referral Hospital (Homa Bay county)
3. Rongo Sub-County Hospital (Migori county)
4. Ahero Sub-County Hospital (Kisumu county)
5. Rabuor Sub-County Hospital (Kisumu county)
 
07-09-2017 View

155.

ECCT/17/08/03   Efficacy and safety of KAF156 in combination with LUM-SDF in adults and children with uncomplicated Plasmodium falciparum malaria
    A Phase 2 interventional, multicenter, randomized open-label study to determine the effective and tolerable dose of KAF156 and Lumefantrine Solid Dispersion Formulation in combination, given once daily for 1, 2 and 3-days to adults and children with uncomplicated Plasmodium falciparum malaria.           
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
KEMRI Siaya
 
02-10-2017 View

156.

ECCT/17/03/02   The Edoxaban Hokusai VTE PEDIATRICS Study
    A PHASE 3, OPEN-LABEL, RANDOMIZED, MULTICENTER, CONTROLLED TRIAL TO EVALUATE THE PHARMACOKINETICS AND PHARMACODYNAMICS OF EDOXABAN AND TO COMPARE THE EFFICACY AND SAFETY OF EDOXABAN WITH STANDARD OF CARE ANTICOAGULANT THERAPY IN PEDIATRIC SUBJECTS FROM BIRTH TO LESS THAN 18 YEARS OF AGE WITH CONFIRMED VENOUS THROMBOEMBOLISM (VTE)   
Principal Investigator(s)
1. Bernhards Ragama Ogutu Ragama
Site(s) in Kenya
1. Gertrudes Hospital (Nairobi City county)
2. Mater Hospital (Nairobi City county)
 
03-10-2017 View

157.

ECCT/17/08/06   Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE)
    Enhancing Preventive Therapy of Malaria In children with Sickle cell anemia in East Africa (EPiTOMISE)   
Principal Investigator(s)
1. Festus Muigai Njuguna
Site(s) in Kenya
Homa Bay County Hospital
 
03-10-2017 View

158.

ECCT/17/06/01   MF/PM Phase III
    An Open Label, Phase III, Randomized Controlled, Multicentre Non-Inferiority Trial to Compare Efficacy and Safety of Miltefosine and Paromomycin with Sodium Stibogluconate and Paromomycin Combination for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa       
Principal Investigator(s)
1. Jane Mbui
Site(s) in Kenya
1. Kimalel Health Centre (Baringo county)
2. Kacheliba sub-county hospital (West Pokot county)
 
04-10-2017 View

159.

ECCT/17/06/02   PAINT Study
    A Phase II, open label, single arm trial to evaluate the pharmacokinetics, safety, tolerability, and antiviral activity of rilpivirine (TMC278) in antiretroviral-naïve HIV-1 infected adolescents and children aged ≥6 to <18 years   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
1. Kenya Medical Research Institute/Walter Reed Project, HIV Program (Kericho county)
2. KAVI Institute of Clinical Research (Nairobi City county)
 
10-10-2017 View

160.

ECCT/17/08/05   Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.
    Phase I Safety and Pharmacokinetic Study of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection.   
Principal Investigator(s)
1. Isaac Tsikhutsu
Site(s) in Kenya
Kenya Medical Research Institute/Walter Reed Project HIV Program, Kericho
 
12-10-2017 View